171 related articles for article (PubMed ID: 37635172)
1. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
Mun SS; Meyerberg J; Peraro L; Korontsvit T; Gardner T; Malviya M; Kyi C; O'Cearbhaill RE; Liu C; Dao T; Scheinberg DA
Cancer Immunol Immunother; 2023 Nov; 72(11):3773-3786. PubMed ID: 37635172
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
Mun SS; Peraro L; Meyerberg J; Korontsvit T; Malviya M; Gardner T; Kyi C; O'Cearbhaill RE; Liu C; Dao T; Scheinberg DA
Res Sq; 2023 May; ():. PubMed ID: 37214945
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
4. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors
Koneru M; Purdon TJ; Spriggs D; Koneru S; Brentjens RJ
Oncoimmunology; 2015 Mar; 4(3):e994446. PubMed ID: 25949921
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Dao T; Pankov D; Scott A; Korontsvit T; Zakhaleva V; Xu Y; Xiang J; Yan S; de Morais Guerreiro MD; Veomett N; Dubrovsky L; Curcio M; Doubrovina E; Ponomarev V; Liu C; O'Reilly RJ; Scheinberg DA
Nat Biotechnol; 2015 Oct; 33(10):1079-86. PubMed ID: 26389576
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
Maruta M; Ochi T; Tanimoto K; Asai H; Saitou T; Fujiwara H; Imamura T; Takenaka K; Yasukawa M
Sci Rep; 2019 Sep; 9(1):13293. PubMed ID: 31527633
[TBL] [Abstract][Full Text] [Related]
9. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
10. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
12. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract][Full Text] [Related]
13. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
Rafiq S; Purdon TJ; Daniyan AF; Koneru M; Dao T; Liu C; Scheinberg DA; Brentjens RJ
Leukemia; 2017 Aug; 31(8):1788-1797. PubMed ID: 27924074
[TBL] [Abstract][Full Text] [Related]
14. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW; Pan CM; Lin YC; Chen MC; Chen Y; Jan CI; Wu CC; Lin FY; Wang ST; Lin CY; Lin PY; Huang WH; Chiang YT; Tsai WC; Chiu YH; Lin TH; Chiu SC; Cho DY
Adv Sci (Weinh); 2023 Jun; 10(17):e2206856. PubMed ID: 37078788
[TBL] [Abstract][Full Text] [Related]
15. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi BD; Yu X; Castano AP; Bouffard AA; Schmidts A; Larson RC; Bailey SR; Boroughs AC; Frigault MJ; Leick MB; Scarfò I; Cetrulo CL; Demehri S; Nahed BV; Cahill DP; Wakimoto H; Curry WT; Carter BS; Maus MV
Nat Biotechnol; 2019 Sep; 37(9):1049-1058. PubMed ID: 31332324
[TBL] [Abstract][Full Text] [Related]
17. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
20. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
